Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And I'm not concerned......
THis is a golden opportunity to average down on a great company.
If you don't feel good about your holdings in Else..then sell and move on..
There was a golden opportunity to ask questions direct to management...but as usual..nothing but stale foul hot air.
Name anything this company has ever made good on...nothing..just promises and bs..Now they dangle a new carrot.....Nigerian gas and oil..Incidentally...a huge amount of internet scams online originate out of NIgeria...
This is yet another one.
Really quite hilarious that anyone can still support this scam of a company.
Sell and move on...
I have scooped up a lot of cheapies the last few days.....
What a bonus!
Nothing has changed.....
Timeframe is where it always was......
Companies expand and grow..and need more captial......
The explanation from the company outlines why they have done this.
I am good with it.
Better sell and move on...I am loading more at this discount.... :)
Something is up!
This happened @ 3:27pm and was announced just after market close...@ 4:09 pm.
IIROC Trading Halt - BABY
Tuesday, June 21, 2022, 4:09 PM ET
TORONTO, June 21, 2022 /CNW/ - The following issues have been halted by IIROC:
Company: Else Nutrition Holdings Inc.
TSX Symbol: BABY
All Issues: Yes
Reason: Pending News
Halt Time (ET): 3:27 PM
IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.
SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions
View original content: http://www.newswire.ca/en/releases/archive/June2022/21/c3804.html
/CONTACT:
For further information about IIROC's trading halt policy, please see Trading Halts & Timely Disclosure (https://www.iiroc.ca/news-and-publications/halts-and-resumptions) at www.iiroc.ca under the Halts and Resumptions tab. Please note that IIROC staff cannot provide any information about a specific halt beyond what is contained in this halt notice. For general information about IIROC, contact IIROC's Complaints and Inquiries team at inquiries@iiroc.ca or 1-877-442-4322 (Option 2). For company-related enquiries, contact the company directly.
Copyright CNW Group 2022
(END) Dow Jones Newswires
" Everything hinges on infant formula, EVERYTHING! That was the plan from the beginning, use the baby and toddler products to pave the road."
And no matter how many times that fact is stated..it is ignored on this board..lol
Instead of yapping on a message board and complaining why not virtually attend the conference and ask your questions direct to the company?
This is 2 days away and allows plenty of time to register and get in line to be heard... Plenty of time for you to be heard with your concerns Janey.
Else Nutrition to Webcast Live at VirtualInvestorConferences.com June 23rd
Monday, June 20, 2022, 1:50 PM ET
Else Nutrition to Webcast Live at VirtualInvestorConferences.com June 23rd
The company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com.
VANCOUVER, British Columbia, June 20, 2022 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC. (BABY) (BABYF) (0YL.F) ("Else" or the "Company"), today announced that Hamutal Yitzhak, CEO, and Co-Founder of the Company, will present live at VirtualInvestorConferences.com on June 23, 2022.
DATE: June 23, 2022
TIME: 10:00 am ET
LINK: https://bit.ly/3LqBLWl
Available for 1x1 meetings: June 29 -- 30, 2022
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.
Learn more about the event at www.virtualinvestorconferences.com.
Provide evidence to back up your assertion that Else is one of those companies.
More fantasy....with no evidence....back up the assertions with fact ...
I'll wait.
Every stock is being pummeled...the global economy is in flux..recession is on the horizon!
It works fine....just finished reading it.
Good points.
Agreed..it's just frustrating to sit back and watch the bs.
Good on you for adding!
The stock should be moving upward with this news...but as we continue to see...it is definitely being manipulated and attacked continually pushing it down for reasons unrelated to how the company is being run or their product offerings.
Shorting has been an issue...hopefully the future holds a better outcome with FDA approval and a Nasdaq listing...
Then let them try and short Baby. :)
That information will never be forthcoming because of the rules and how the game is played. I have tried repeatedly to explain that and having been through this circus before many times I know how it always turns out for shareholders.
It never does in 99% of these stories.
So..throwing more and more money or any money at all was always bs imo and that of many other shareholders.
....and demanding to see what you're not entitled to see or to see what continues to be prevented from you seeing will only continue......
Sorry if you don't like the messenger(S) or the messages.....
Wasting ones' precious time on bs like this where it's almost 100% guaranteed that there is nothing for us.... left for us...well..this whole story as told on this board was nothing but a fairytale and just because something is talked about over and over doesn't mean it's true..will be true or in fact has any chance at all of working out in the affirmative for us.
Believe what you want and demand what you think you're entitled to as long as those hopes and dreams are based in reality and in the case of UOIP...they aren't..never have been...there's been deception and bs peddled here as truth and it cuts both ways.....
I chose to believe and trust based on my personal life experiences and also trust in people that have proven to be trustworthy and dependable..like Zomby....and we go back.
LOL..if u say so.....
I think only the common shares are tradeable right now.
They had offered warrants a while ago when they were raising money but I don't believe they're free trading.
I will check into this...
https://ca.finance.yahoo.com/news/else-nutrition-announces-warrant-extension-210500658.html
All I could find.
I just picked up a bunch more on the US side @ 1.06...no issues.
Tuesday, May 31, 2022, 7:00 AM ET
Else Successfully Completes Second Preclinical Study on the Path For FDA Approval of World's First Whole Plant, Soy-Free Infant Formula
-- With products for toddlers and kids already in the market, Else has made
tremendous progress towards becoming a player in the $80 billion global
infant formula market.
VANCOUVER, British Columbia, May 31, 2022 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC. (BABY) (BABYF) (0YL.F) ("Else" or the "Company"), the Plant-Based baby, toddler, and children nutrition company, is pleased to announce that it has concluded a second successful preclinical study on its Plant-Based infant formula, which is a crucial phase for bringing the Company's innovative 0-12 month infant formula to market.
The study's results showed proper protein efficiency in a preclinical model; a significant step on the path with the Food and Drug Administration (FDA) and other regulatory authorities to demonstrate the protein bioavailability of Else's infant formula.
"This is a big step forward for the Company," said Hamutal Yitzhak, CEO & Co-Founder of Else Nutrition. "Since inception, our vision has been to fill the major market gap for an alternative to dairy and bring a whole-food, plant-based, soy-free infant formula to millions of families worldwide. These results mark further validation of our formulation, as we continue to push ahead in seeking FDA approval."
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at Milan's Global Food Innovation Summit. Else Plant-Based Complete Nutrition for Toddlers was recently ranked as the #1 Top Seller in the baby and toddler formula category on Amazon. The Company recently received the World Plant-Based Award for "Best dairy alternative product" in New York at World Plant-Based Expo in late 2021. The holding company, Else Nutrition Holdings Inc., is a publicly-traded company listed on the Toronto Stock Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else's Executives include leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics, and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children's Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children's Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.
For more information, visit elsenutrition.com or @elsenutrition on Facebook and Instagram.
Investor Relations Contact:
Lytham Partners, LLC
Mr. Ben Shamsian
New York | Phoenix
E: shamsian@lythampartners.com
P: 646-829-9701
And shareholders as usual..are at the bottom of the pecking order....
This will take years to be resolved...and if in fact there is anything returned.... shareholders will still get next to nothing....
The complexities involved with all the money that's already been disseminated...well...let's just say...good luck reconciling everything that has been done that has occurred because of illegalities.
It isn't just Carter and Deidre...lawyers are also involved..
This will drag on ad infinitum.
That's just how it goes.
Glad I stayed on the sidelines
Did you read the pr today?..They have now produced the formula and the FDA will start the evaluation process....clinical trials....etc...this is moving ahead.....
Within 2 years or less this will be on the shelves...and don't lose site of the fact as to the shit show currently going on with commercial baby formula that this offering from Else is not being eyed seriously as a great solution to not only allergies but the total elimination of toxic materials that have been found in all commercially produced formulas currently available...hence the shortages now...as the FDA stepped in and shut factories down.
I like this line from today's pr...
"Following the commercial production, Else will conduct clinical trials to validate product safety and benefits for regulatory approval of its infant formula, which is anticipated to become the Company's flagship product."
This is where the $$$$$$ are being spent..and rightfully so!
The likelihood of that happening is low..considering the reason for the shortage in the first place.
This is why they're putting all the effort into working with leading pediatricians...so they'll understand and suggest Else to their patients (new mothers).
There is nothing on the market that Else can be compared to...
The product will be disruptive to the already established marketplace and as we have seen..these companies have issues with purity in many cases with everything from toxic metals showing up to other ingredients that make babies sick such as lactose and soy.
The work continues and is ongoing and I agree ..this all takes time....but I think a lot of the work has been going on for a while already and they are focussed exactly where they need to be....just as you have pointed out...this is an arduous process.
Else has already been shown to have the same nutritional footprint as current formulas without all the drawbacks and sensitivities experienced by so many babies and toddlers.....now they have to navigate through the FDA process,,,which is where we are now.
The assembled team @ Else is like an all star team of who's who from within the baby food industry.
They know exactly how and what they're doing.
It isn't just about simple marketing as some would have you believe..LOL
I agree with everything you wrote except your time line..I'd say 2 years max...already been here close to 3 years.
Hamutal Yitzhak, CEO of Else Nutrition commented: “We are in the very early stages of a multi-year revenue growth phase, as we are positioned to disrupt the $80 billion baby nutrition market. We have set the stage for this performance with thousands of retail points of sale, multiple SKUs ranging from 6M+ to 13Y products, strong distributors and major strategic partners that intend to drive the Else brand as a revolutionary protein alternative for babies, toddlers and kids.”
Repetitus......
I said exactly the same thing..social media..social influencers..working the secondary product.....
for the purpose of the name brand..Else in anticipation of the baby formula launch.....so there is marketing.
Executing on their plan according to their schedule and plans....
I can only surmise....
One only has to review their presentations over the last 2 years to see what and where their focus is...
But I don't know exactly what they are doing.....time frames etc...I only know that FDA approval is job number one and whining about poor sales of secondary products seems to be the focus for some here...which makes me laugh.
Even when the company and posters spell it all out in b and w....the same bs is posted about poor sales and no marketing program...
How many f#cking times does it have to be said here..they are not wasting any powder on secondary offerings... I pointed out yesterday..there are zero Else products for new mothers..yet some here keep harping on how there is no marketing for new mothers...
There is no product right now...for new mothers.
So where is the logic in spending big $$$$ on marketing to new mothers.
The have social media and influencers doing a lot of the marketing for the secondary products for now..and that is a good plan imo.
Maybe because some her are antiques and don't go on social media they assume there is no marketing.
But again..this has been stated over and over..and then the same tired bs gets reposted about marketing to new mothers..LOL
LOL...sell and move on...
You reference a business plan...do you know what their plan is..concisely....because I don't off the top of my head..I only know that the company is very happy with how everything is going...ACCORDING TO THEIR PLAN....
As I mentioned, they are saving their powder for the formula....the only reason Else exists in the first place.... all the toddler and child products and eventually adult nutrition products are a spin off of all the r and d and development of the infant formula concept....
The company has no debt,,has cash on hand and is executing on their plan....
and that's bad?
I think one of the big problems here is that we have all gotten used to playing the penny stock garbage that Ihub seems to foster and as such when a real company with a legitimate chance at creating a wonderful marketplace for their products appear, we tend to apply all the bs we have absorbed from dwelling in all the penny stock garbage which is driven by criminals and bs artists....and can't see the forest for the trees when a real opportunity falls in our laps.
If people are so dissatisfied with how Hamital and her team are doing things..then it's really quite simple....vote with your shares...sell and move on....
For me and a few of us that really understand what is happening here and the time frame...we continue to add @ these levels....and happy to have that opportunity.
I started this board a couple of years ago and brought attention to Else when it was trading in the 29 cent range.
I have had realistic expectations from the time of the purchase of my first 29 cent shares as to how long it will take for the formula to hit the shelves. I didn't invest in this company because of toddler products.
Their product is already proven....all that's holding it back is FDA approval which will come...a tremendous amount of r and d has already gone down..they know exactly what they have on their hands....a disruptive product..fact.
I think you're missing my point here...the numbers while real don't reflect the reason for the company to exist in the first place...
Let's talk numbers when the formula is launched...the rest of this is just secondary noise...and the main reason why these numbers are pale.
Patience grasshopper.
RADER..your lawyer...next.....
True...but again..this is all based on their secondary offerings and not the focus of why the company exists in the first place.
Read your own posts..you keep referring to new mothers...Else currently doesn't offer anything for new mothers with babies....
But yet you keep insisting they should spend millions on marketing a product that as of yet isn't available.
That makes no sense..sorry.
Why invest marketing dollars if the reason your company exists in the first place, the infant baby formula..which requires FDA approval isn't ready for prime time....YET
All this other stuff for toddlers and children is secondary...and I don't blame them one bit for not blowing their marketing budget on these secondary offering(s)...
You seem to think you know more than the people behind Else.
That's quite funny to me.
Monday, May 16, 2022, 7:00 AM ET
Else Nutrition Provides Solid 1Q2022 Financial Results
Reporting substantial 26% revenue growth QoQ
Conference call will be held on May 16th at 11AM ET
VANCOUVER, British Columbia, May 16, 2022 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC (BABY) (BABYF) (0YL.F) ("Else" or the "Company") the Plant-Based baby, toddler and children nutrition company, today reported first-quarter 2022 financial results for the period ending March 31, 2022. The financial statements and MD&A are available on SEDAR under the Company's profile.
First Quarter 2022 Financial Highlights
-- Revenues were $1.6M, a 26% increase versus $1.3M in 4Q21, driven by the
expansion of our toddler products across all channels, and the
introduction of the new Kids Complete Nutritional shake product line.
-- Sales on Amazon.com increased 40% sequentially versus 4Q21, a strong
acceleration from prior periods.
-- Else products are now sold in over 1,300 stores.
-- Cash balance as of March 31, 2022 was $19.8M (including restricted cash
and short-term bank deposit).
-- The Company had no loans liability as of March 31, 2022.
-- Graduated to the Toronto Stock Exchange.
Recent Business Highlights
-- Expanded US retail presence to more than 1,300 stores and continue to
increase retail sales velocity. Several retailers have already added the
new Kids products to their range.
-- Successfully listed on Walmart.com and Kroger-owned online platforms.
-- Following the success on Amazon in the US, Else was invited by Amazon EU
to launch a European unified account that will allow Else to sell its
products on major Amazon European marketplaces including the UK, Germany,
France, Italy, Spain, the Netherlands, and Sweden, representing a market
with more than 300M people.
-- Expanded ecommerce and retail distribution of the kid's product line to
include KeHE, UNFI, Walmart.com, Thrive Market, and additional channels.
-- Successfully launched its third product, Else(TM) Toddler Omega Complete
& Balanced Nutrition drink on Amazon.com. and on the Company's e-store,
followed by retail distribution in select retail outlets.
-- Successfully launched its fourth product, Else(TM) Super Cereal, safe
from heavy metals. Else Super Cereal, the first US cereal brand safe from
heavy metals, certified clean label purity award was launched on
Amazon.com and on the Company's e-store, to be followed by retail
distribution in select retail outlets.
-- Acceptance of Supplemental Nutrition Assistance Program (SNAP) for Else
products by Amazon.com.
-- Launched an intensive HCP initiative in the US that includes a dedicated
HCP website and a campaign to reach more than 80,000 pediatricians. This
effort is led by Mr. Mike Glick, Else' North America GM, a former Abbott
Senior Director of Pediatric and Adult Nutrition.
-- Conducted an Independent Research Survey Demonstrating that Else'
Products dramatically Improved Major Feeding Related Disorders & Symptoms
in large majority of children.
-- Prepared to launch a clinical study with Children's Hospital Colorado and
Denver School of Medicine to validate growth benefits of Else's
Plant-Based Nutrition product.
Management Commentary
Hamutal Yitzhak, CEO of Else Nutrition commented: "We are in the very early stages of a multi-year revenue growth phase, as we are positioned to disrupt the $80 billion baby nutrition market. We have set the stage for this performance with thousands of retail points of sale, multiple SKUs ranging from 6M+ to 13Y products, strong distributors and major strategic partners that intend to drive the Else brand as a revolutionary protein alternative for babies, toddlers and kids."
"We are seeing a strong acceleration in sales on Amazon.com, driven by new and existing customers. Revenues on Amazon.com increased by 40% QoQ in 1Q22. In addition, the number of Else subscribers on Amazon.com crossed the 1,000 mark in early April. Our retailers are experiencing solid and growing sales velocity of our products, and we are seeing growing reorders with many of those retailers. We expect to triple our door count to roughly 4,000 by the end of 2022."
"In recent months we expanded our product offerings, with the launch of our Kids Shakes in 3Q21, and with our Toddler Omega and Super Cereal in 2022. During 2022 our product range will grow to roughly 8-10 products and over 20 SKUs in the US alone."
"International expansion will be a focus for Else in 2022. In 2Q22 we will launch in Canada via Amazon.ca, our own e-store, and in natural food retailers and independents, regional grocery and drug retailers. In addition, in Q3 we expect to enter the UK and Western Europe via Amazon. We also expect to start selling online in China (Cross Border) in H2 2022. We feel very confident this growth rate is sustainable and will continue going forward."
FDA Update
-- In Q4 2021 Else concluded a successful preclinical safety study of its
plant-based infant formula, as part of the pathway to bring its Infant
formulation to market.
-- The study results demonstrated proper growth, similar to dairy-based
infant formula, in a neonatal preclinical model, which is a key first
step on the path with the US Food and Drug Administration (FDA), as well
as with other regulatory authorities, to demonstrate safety and nutrient
bioavailability of the infant formula and its ingredients. The results of
the study will be presented in two key scientific meetings focused on
pediatric nutrition and will be published in scientific peer-reviewed
journals. Else is in close communication with the FDA, sharing its plans
and results to receive their guidance throughout the process of Else's
infant formula development.
-- Else working on preparations for four clinical studies planned for 2022,
one major study to gain FDA infant formula approval, and three others to
validate product safety, tolerance and hypo allergenicity claims.
-- In 2022 we plan to continue our research activity demonstrating the
safety of the infant formula as well as provide scientific support for
our products including preparations for additional clinical studies.
Conference Call
Hamutal Yitzhak, CEO and Co-Founder, will hold a conference call to discuss the quarter's financial results at 11:00 a.m. (Eastern Time) on May 16, 2022.
Interested parties can listen via a live webcast, from the link available in the Investors section of the Company's website or at https://app.webinar.net/WEmKaEqaJy3.
A replay will be available after the call, in the Investors section of the Company's website at https://app.webinar.net/WEmKaEqaJy3.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at the Global Food Innovation Summit in Milan. Else Plant-Based Complete Nutrition for Toddlers was recently ranked as the #1 Top seller in the baby and toddler formula category on Amazon. The Company recently received the World Plant-Based Award for "Best dairy alternative product" in New York at World Plant-Based Expo in late 2021. The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed on the Toronto Stock Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else's Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children's Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children's Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.
For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.
Investor Relations Contact:
Lytham Partners, LLC
Mr. Ben Shamsian
New York | Phoenix
E: shamsian@lythampartners.com
P: 646-829-9701
Toronto Stock Exchange
Neither the Toronto Stock Exchange nor its regulation services provider (as that term is defined in the policies of the Toronto Stock Exchange) a responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "will" or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company's financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management's perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ
(MORE TO FOLLOW) Dow Jones Newswires
Bingo and been said here a few times previously.
Better sell it all tomorrow...the sky is falling ..lol